STOCK TITAN

[Form 4/A] Sera Prognostics, Inc. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A

Sera Prognostics director Sandra Lawrence reported an amended Form 4 showing the sale of 1,560 shares of Class A common stock at a weighted average price of $3.05, leaving her with 21,153 shares beneficially owned. The sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2025, and the Form 4 amendment corrects an administrative error in the originally reported share count. The filer states the reported price is a weighted average for multiple transactions ranging from $2.99 to $3.12 and offers to provide a breakdown on request.

La direttrice di Sera Prognostics, Sandra Lawrence, ha riportato una modifica al Form 4 che mostra la vendita di 1.560 azioni di Classe A a un prezzo medio ponderato di 3,05 dollari, lasciando una partecipazione di 21.153 azioni detenute beneficiariamente. Le vendite sono state eseguite nell'ambito di un piano di trading Rule 10b5-1 adottato dall'interessata il 10 giugno 2025, e la modifica del Form 4 corregge un errore amministrativo conteplato nel conteggio iniziale delle azioni. Il dichiarante precisa che il prezzo indicato è una media ponderata di diverse operazioni che vanno da 2,99 a 3,12 dollari e si offre di fornire una suddivisione dei dati su richiesta.

La directora de Sera Prognostics, Sandra Lawrence, reportó una versión modificada del Formulario 4 que muestra la venta de 1.560 acciones comunes de Clase A a un precio medio ponderado de 3,05 dólares, quedando en posesión de 21.153 acciones de forma beneficiosa. Las ventas se ejecutaron bajo un plan de negociación Rule 10b5-1 adoptado por la informante el 10 de junio de 2025, y la enmienda del Formulario 4 corrige un error administrativo en el recuento original de acciones. La presentante indica que el precio informado es una media ponderada de múltiples operaciones que oscilan entre 2,99 y 3,12 dólares y ofrece proporcionar un desglose a solicitud.

Sera Prognostics의 이사 Sandra Lawrence는 가중평균가 3.05달러로 A클래스 보통주 1,560주 매도 기록을 수정한 Form 4를 보고했으며, 그로 인해 그녀의 수혜상 주식 수는 21,153주가 되었습니다. 매매는 보고자에 의해 2025년 6월 10일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, Form 4 수정은 원래 보고된 주식 수에서의 행정적 오류를 시정합니다. 제출자는 보고된 가격이 2.99달러에서 3.12달러까지의 여러 거래에 대한 가중평균이며 요청 시 분해 내역을 제공하겠다고 밝힙니다.

La directrice de Sera Prognostics, Sandra Lawrence, a publié une version modifiée du Formulaire 4 indiquant la vente de 1 560 actions ordinaires de classe A à un prix moyen ponderé de 3,05 dollars, ce qui lui laisse 21 153 actions détenues beneficialment. Les ventes ont été exécutées dans le cadre d'un plan de trading Rule 10b5-1 adopté par la personne déclarant le 10 juin 2025, et l'amendement du Formulaire 4 corrige une erreur administrative dans le décompte initial des actions. Le déclarant indique que le prix indiqué est une moyenne pondérée de plusieurs transactions allant de 2,99 à 3,12 dollars et propose de fournir une ventilation sur demande.

Die Direktorin von Sera Prognostics, Sandra Lawrence, hat einen geänderten Form 4 berichtet, der den Verkauf von 1.560 Class-A-Stammaktien zu einem gewichteten Durchschnittspreis von 3,05 USD ausweist, wodurch sie 21.153 Aktien direkt besitzt. Die Verkäufe wurden im Rahmen eines von der meldenden Person am 10. Juni 2025 übernommenen Rule-10b5-1-Handelsplans durchgeführt, und die Änderung des Form 4 korrigiert einen administrativen Fehler in der ursprünglich gemeldeten Stückzahl. Der Melder gibt an, dass der angegebene Preis ein gewogenes Mittel mehrerer Transaktionen sei, die von 2,99 bis 3,12 USD reichen, und bietet auf Anfrage eine Aufschlüsselung an.

أفادت نائبة مدير Sera Prognostics ساندرا لورانس بوجود تعديل في النموذج 4 يظهر بيع 1,560 سهماً من الأسهم العادية من الفئة أ بسعر متوسط مرجح قدره 3.05 دولارات، مما يجعل حوزتها 21,153 سهماً بشكل مستفيد. تمت عمليات البيع بموجب خطة تداول Rule 10b5-1 اعتمدتها الشخص المبلّغ عنها في 10 يونيو 2025، وتصحّح تعديلات النموذج 4 خطأً إداريًا في عدد الأسهم الذي تم الإبلاغ عنه أصلًا. تقول المبلّغة إن السعر المبلغ عنه هو متوسط مرجح لعدة معاملات تتراوح من 2.99 إلى 3.12 دولار وتعرض تقديم تفصيل عند الطلب.

Sera Prognostics 的董事 Sandra Lawrence 报告了一份经修订的 Form 4,显示以2.99-3.12美元的加权平均价格出售了1,560股A类普通股,使她拥有21,153股的受益所有权。 这些卖出是在她于2025年6月10日采取的 Rule 10b5-1 交易计划下执行的,Form 4 的修订纠正了最初报告的股数中的行政错误。申报人表示所报道的价格是多笔交易的加权平均值,价格区间为2.99美元至3.12美元,如有需要可以提供分解明细。

Positive
  • Transaction executed under a Rule 10b5-1 trading plan, indicating preplanned trades rather than opportunistic insider selling
  • Amended Form 4 corrects an administrative error, improving disclosure accuracy and compliance
  • Weighted average price and price range disclosed, allowing parties to request detailed breakdowns of sale prices
Negative
  • Director sold 1,560 shares, reducing beneficial ownership to 21,153 shares
  • Original filing contained an administrative error requiring an amendment

Insights

TL;DR: Routine 10b5-1 sale by a director; amendment fixes reporting error, limited investor impact.

The transaction reflects a small-scale, planned disposition executed under a documented 10b5-1 plan, which generally indicates pre-scheduled trading rather than opportunistic insider selling. The amendment correcting the originally reported share count improves transparency and regulatory compliance. The disclosure of the weighted average sale price and range allows reconstruction of trade prices if requested, supporting clarity for investors and regulators.

TL;DR: Governance controls appear functional: use of a 10b5-1 plan and corrective amendment demonstrate adherence to disclosure norms.

The filing shows use of an affirmative-defense trading plan and an explicit correction to a prior filing, which are positive governance signals. The amendment indicates oversight and willingness to correct administrative mistakes. There is no indication of undisclosed related-party arrangements or changes in control from the document.

La direttrice di Sera Prognostics, Sandra Lawrence, ha riportato una modifica al Form 4 che mostra la vendita di 1.560 azioni di Classe A a un prezzo medio ponderato di 3,05 dollari, lasciando una partecipazione di 21.153 azioni detenute beneficiariamente. Le vendite sono state eseguite nell'ambito di un piano di trading Rule 10b5-1 adottato dall'interessata il 10 giugno 2025, e la modifica del Form 4 corregge un errore amministrativo conteplato nel conteggio iniziale delle azioni. Il dichiarante precisa che il prezzo indicato è una media ponderata di diverse operazioni che vanno da 2,99 a 3,12 dollari e si offre di fornire una suddivisione dei dati su richiesta.

La directora de Sera Prognostics, Sandra Lawrence, reportó una versión modificada del Formulario 4 que muestra la venta de 1.560 acciones comunes de Clase A a un precio medio ponderado de 3,05 dólares, quedando en posesión de 21.153 acciones de forma beneficiosa. Las ventas se ejecutaron bajo un plan de negociación Rule 10b5-1 adoptado por la informante el 10 de junio de 2025, y la enmienda del Formulario 4 corrige un error administrativo en el recuento original de acciones. La presentante indica que el precio informado es una media ponderada de múltiples operaciones que oscilan entre 2,99 y 3,12 dólares y ofrece proporcionar un desglose a solicitud.

Sera Prognostics의 이사 Sandra Lawrence는 가중평균가 3.05달러로 A클래스 보통주 1,560주 매도 기록을 수정한 Form 4를 보고했으며, 그로 인해 그녀의 수혜상 주식 수는 21,153주가 되었습니다. 매매는 보고자에 의해 2025년 6월 10일에 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, Form 4 수정은 원래 보고된 주식 수에서의 행정적 오류를 시정합니다. 제출자는 보고된 가격이 2.99달러에서 3.12달러까지의 여러 거래에 대한 가중평균이며 요청 시 분해 내역을 제공하겠다고 밝힙니다.

La directrice de Sera Prognostics, Sandra Lawrence, a publié une version modifiée du Formulaire 4 indiquant la vente de 1 560 actions ordinaires de classe A à un prix moyen ponderé de 3,05 dollars, ce qui lui laisse 21 153 actions détenues beneficialment. Les ventes ont été exécutées dans le cadre d'un plan de trading Rule 10b5-1 adopté par la personne déclarant le 10 juin 2025, et l'amendement du Formulaire 4 corrige une erreur administrative dans le décompte initial des actions. Le déclarant indique que le prix indiqué est une moyenne pondérée de plusieurs transactions allant de 2,99 à 3,12 dollars et propose de fournir une ventilation sur demande.

Die Direktorin von Sera Prognostics, Sandra Lawrence, hat einen geänderten Form 4 berichtet, der den Verkauf von 1.560 Class-A-Stammaktien zu einem gewichteten Durchschnittspreis von 3,05 USD ausweist, wodurch sie 21.153 Aktien direkt besitzt. Die Verkäufe wurden im Rahmen eines von der meldenden Person am 10. Juni 2025 übernommenen Rule-10b5-1-Handelsplans durchgeführt, und die Änderung des Form 4 korrigiert einen administrativen Fehler in der ursprünglich gemeldeten Stückzahl. Der Melder gibt an, dass der angegebene Preis ein gewogenes Mittel mehrerer Transaktionen sei, die von 2,99 bis 3,12 USD reichen, und bietet auf Anfrage eine Aufschlüsselung an.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lawrence Sandra AJ

(Last) (First) (Middle)
C/O SERA PROGNOSTICS, INC.
2749 EAST PARLEYS WAY, SUITE 200

(Street)
SALT LAKE CITY UT 84109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SERA PROGNOSTICS, INC. [ SERA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
09/09/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/09/2025 S(1) 1,560 D $3.05(2) 21,153 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction(s) reported on this Form 4 was/were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.99 to $3.12, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Remarks:
This Form 4 amendment is being filed to correct the original Form 4 filed on September 9, 2025, which included the incorrect number of shares sold by the Reporting Person in Table I due to an administrative error.
/s/ Benjamin G. Jackson, Attorney-in-fact 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SERA director Sandra Lawrence disclose in the Form 4/A?

She sold 1,560 shares of Class A common stock at a weighted average price of $3.05, leaving 21,153 shares beneficially owned.

Were the sales part of a trading plan for SERA insiders?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2025.

Why was the Form 4 amended for SERA (Sandra Lawrence)?

To correct an administrative error in the originally reported number of shares sold in Table I.

What prices were the SERA shares sold at?

The weighted average price was $3.05, with individual transactions in the range of $2.99 to $3.12.

Can investors get a breakdown of each sale price for the SERA shares?

Yes. The reporting person offers to provide the number of shares sold at each separate price upon request to the SEC staff, the issuer, or any security holder.
Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Latest News

SERA Latest SEC Filings

SERA Stock Data

122.18M
32.89M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY